Related Experiment Video
Updated: May 15, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
IL-27 in tumor immunity and immunotherapy
Gopal Murugaiyan1, Bhaskar Saha
1Centre for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston 02115, MA, USA. mgopal@rics.bwh.harvard.edu
Trends in Molecular Medicine
|January 12, 2013
Summary
Interleukin-27 (IL-27) enhances natural killer (NK) cells and cytotoxic T cells (CTLs) to combat cancer. Modulating IL-27 shows promise for future cancer immunotherapy strategies by boosting antitumor immunity.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Inflammation plays a key role in cancer progression and metastasis.
- Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) are crucial for eliminating early tumors and limiting metastasis.
Purpose of the Study:
- To review the role of Interleukin-27 (IL-27) in modulating immune responses against cancer.
- To highlight the potential of IL-27 as a therapeutic target for cancer immunotherapy.
Main Methods:
- Review of existing literature on IL-27 function in cancer immunity.
- Analysis of IL-27's effects on immune cells and tumor microenvironment.
Main Results:
- IL-27, produced by antigen-presenting cells (APCs), promotes NK cell and CTL development, enhancing antitumor immunity.
- IL-27 exhibits antiangiogenic and antimetastatic activities, contributing to local antitumor effects.
Conclusions:
- IL-27 is a critical regulator of both innate and adaptive immune responses in cancer.
- Targeting IL-27 presents a promising strategy for developing novel cancer immunotherapies.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...